General News
Published September 14, 2020
For all fully insured, individual, and self-funded groups who opted into cost share waivers
Premera Blue Cross will be extending cost share waivers for COVID-19 treatment through December 31, 2020. This means that members will not pay a cost share requiring treatment for COVID-19. FDA-approved diagnostic testing and the related provider visit cost share waivers are extended through October 23, 2020. This is in compliance with federal rules.
All other treatments and services including hospitalizations will be subject to the usual benefits and cost shares. We will continue to evaluate guidance and the scope of COVID-19 and adjust as needed.
For more information regarding COVID-19 testing and treatment, you may visit our COVID-19 FAQ for employers or contact your Premera representative or producer.